Intellia Therapeutics' second quarter EPS met estimates while revenue missed; lonvo-z BLA submission remains on track for 2H 2026.

Intellia Therapeutics reported second quarter collaboration revenue of $7.7 million, a significant decrease from $14.2 million in the prior year, missing analyst expectations. The company posted a net loss of $0.80 per share, which was in line with consensus estimates. The primary focus remains on the clinical and regulatory progress of its lead candidates, particularly lonvo-z.

Key Highlights

• The company reported positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in Hereditary Angioedema (HAE).
• Intellia expects the FDA to accept its Biologics License Application (BLA) for lonvo-z in the second half of 2026, with a potential U.S. launch in the first half of 2027.
• The company ended the second quarter with a strong cash position of $628.4 million, which is expected to fund operations at least into 2028.